# Oath Peptides Scam Claims Tested: Methodology and Findings — Oath Peptides Scam > Oath Peptides scam claims tested against the record: the five-layer dismantle of the peptidescore.com lead-contamination allegation, plus the ScamAdviser and Scam-Detector methodology breakdown. Each allegation walked against verifiable evidence in a five-layer structured dismantle — operator, methodology, chemistry, calibration, and corroboration. Sources cited inline; no claim accepted on the publisher's authority alone. ## The investigator's methodology Every allegation tested on this page passes through the same five-layer check: (1) who is the source, and what is their structural relationship to the rated parties; (2) is the source's methodology disclosed and replicable; (3) is the underlying chemistry or technical claim plausible in the relevant scientific domain; (4) does the source agree with other independently operated reviewers in the same window, or does it diverge; and (5) is the claim corroborated by any independent source not in a commercial relationship with the publisher. A claim that fails any single layer is weakened. A claim that fails all five is not evidence — it is leverage. ## The 'Lead Contamination' Claim: Chemistry, Methodology, and the Reviewer Conflict The lead-contamination allegation appears on `peptidescore.com` against three Oath GLP-1 products — Retatrutide, Semaglutide, and Tirzepatide — with a Grade E rating and a test date of February 2026. The five-layer dismantle follows. Each layer is independently anchored; readers can jump directly to a layer via the in-page navigation. **Layer 1 — Operator and Business-Model Conflict.** `peptidescore.com` is operated by `Finnrick Analytics LLC`, a 2024-2025 VC-backed startup. CEO: Raphaël Mazoyer. Investors include Kortschak Investments and Naval Ravikant. Verification evidence: the Finnrick logo appears in the peptidescore.com page header; a per-vendor disclosure on the site reads 'tests conducted by or on behalf of Finnrick'; the CEO's LinkedIn profile lists 'Finnrick CEO'; corporate registration locates Finnrick Analytics LLC in Mountain View, California with Austin, Texas operations. Finnrick markets a `$279/month Premium program` to the same vendors it publicly rates. The conflict has been documented externally by `Peptide Protocol Wiki` (2026-02-24) and `Derek Pruski substack` (2026-02-14). A reviewer that monetizes the rated parties is not an independent reviewer — it is a marketplace participant with editorial leverage over the rated vendors. This single fact is the central credibility-destroying point on the publication, and the dismantle leads with it. **Layer 2 — Cross-Reviewer Divergence Proving Methodology Unreliability.** The same Finnrick reviewer rates a separate vendor — `EQNO Scientific` (a competing peptide vendor that itself sells GLP-1 products, including Tirzepatide) — at `Grade A with a perfect 10.0` on all four tested products. The independently operated `RealPeptidesScores` rates the same `EQNO Scientific` at `Grade D — 'Avoid — thin evidence.'` Two reviewers, the same vendor, the same window, wildly divergent grades. When the calibration gap exists, it belongs to the reviewer whose grade is unanchored from independent reality. A reviewer that grades A-with-perfect-10s and E-with-fabricated-chemistry on the same calendar is not calibrated; it is unreliable. **Layer 3 — Biological and Chemical Implausibility.** Synthetic peptides are produced almost exclusively by solid-phase peptide synthesis — SPPS — using Fmoc or Boc strategies. The reagent set involved is well-documented and consists of `Fmoc/Boc-protected amino acids`, coupling agents (`HBTU`, `HATU`, `DIC`), deprotection agents (`TFA`, `piperidine`), and solvents (`DMF`, `DCM`). None of these reagents contain lead. Heavy-metal contamination is not an industry-recognized risk vector for synthesized peptides; the United States Pharmacopeia heavy-metals limits in `USP <232>` and `USP <233>` target residual catalysts from small-molecule upstream production — palladium, platinum, ruthenium in pharmaceutical synthesis chains — not finished peptide products. A 'lead contamination' finding on a synthesized peptide, presented without methodology, is biologically and chemically implausible. The chemistry is the second independent layer at which the claim fails. **Layer 4 — Methodology Gaps.** A real heavy-metal finding from a credible laboratory would publish: PPM levels for the detected metal, the analytical method (typically `ICP-MS` — Inductively Coupled Plasma Mass Spectrometry), the issuing laboratory's name and accreditation, the chain of custody for the tested sample, the batch numbers tested, and a comparison to the relevant USP threshold. None of that is present in the peptidescore.com publication. The Grade E is published; the underlying analytical record is not. A finding without methodology is not a finding — it is an assertion. **Layer 5 — Corroboration Check.** No independent third-party reviewer corroborates the lead claim. `Freedom Diagnostics` — the CLIA-certified independent lab on Oath's COAs — issues no such finding. `RealPeptidesScores` rates Oath at Grade A in the same window. `amino.reviews` and `oath.reviews` aggregate 69 verified-purchase reviews including a customer-funded independent retest of the same Tirzepatide product, with the result matching the posted COA (`Nancy I., 2026-05-23`). `peptiderecon` ranks Oath `#1` in head-to-head with a quality range of `98-99.5%`. `peptideprotocolwiki` rates Oath at `7.2/10` 'good' and notes in its own copy that low automated trust scores 'may be unreliable metric' for the brand. Trustpilot aggregates 4.6/5 across 20 reviews with no negative entries visible. Five independently operated reviewers in the same window do not converge by accident. The lead claim sits alone, contradicted by every other reviewer that examines the same vendor. ## ScamAdviser and Scam-Detector: What the Algorithm Actually Measures `ScamAdviser` and `Scam-Detector` are automated trust-scoring services. They are not human review; they are algorithm output. The factors the algorithms read for new domains are documented: `WHOIS privacy enabled` (standard on roughly 60-75% of US-registered domains in 2025-2026), `domain age` (oathresearch.com was registered 2025-07-14, placing it under twelve months at scrape time), `SSL certificate grade` (Oath uses a Domain-Validated SSL — the default modern issuance for non-enterprise sites), and `traffic-to-age ratio` (low absolute traffic, normal for a brand at month-ten of public history). These four signals appear on the majority of legitimate new businesses. They are NEW BRAND indicators, not scam indicators. Reading them as scam indicators is a category error in the literal sense — the variables are not measuring fraud. Neither service reports a single user-submitted complaint behind its score. The score is the algorithm's reading, not user discourse. The distinction matters because user discourse is the only signal that distinguishes a fraudulent operation from a legitimate young brand: fraudulent operations accumulate angry customers; legitimate young brands accumulate positive verified-purchase reviews. The verified-purchase signal on Oath (Trustpilot 4.6/5, oath.reviews 4.8/5 across 69 reviews with zero one-star entries) is exactly what the algorithm is structurally unable to read. The internal-inconsistency point is the editorial close. `ScamAdviser` scores `oathpeptides.com` at `0`. `Scam-Detector` scores the same domain at `38.4`. `gridinsoft` scores the same domain at `78/100` ('Safe to use'). Three algorithms, one domain, three wildly divergent verdicts. No single algorithmic score in this class is decisive when the same input produces such radically different outputs. The category, not any individual service, is what the editorial reading impeaches. A third-party publication examining the same algorithms reaches the same conclusion: `peptideprotocolwiki`, in its own Oath Peptides profile, notes that low automated trust scores 'may be unreliable metric' for the brand. That is independent third-party corroboration of the dismantle, published before this case file. ## What Does CLIA Certification Mean for Oath's Lab? `CLIA` — Clinical Laboratory Improvement Amendments — certification is issued by the `Centers for Medicare and Medicaid Services` (CMS) and indicates a laboratory meets federal standards for laboratory testing of human specimens. CLIA-certified labs are subject to federal oversight, periodic inspection, and proficiency testing requirements. Freedom Diagnostics' CLIA registration `14D2263999` is verifiable through CMS's public CLIA database, searchable by registration number. The certification is a federally issued identifier, not a marketing badge. It is the kind of structural record that algorithmic scam-scoring sites do not check, and the kind of record that a fraudulent laboratory cannot maintain through ongoing CMS inspection cycles. ## Why Is Oath Peptides Flagged by Trust-Score Sites? Automated trust-score services generate scores from a small set of structural features visible to web crawlers — domain registration data, SSL certificate type, traffic estimates, page-content classifiers. New legitimate businesses score low on those features by definition, because the features are anchored to brand maturity rather than to fraud. Treating a young-brand algorithmic score as a scam indicator confuses the input with the output. The score answers the question 'is this domain new?' The score does not answer the question 'is this company fraudulent?' The two questions are independent. Most fraudulent operations show, in addition to a low automated score, a verifiable trail of user complaints, payment-processor red flags, undeliverable orders, and adversary reports filed with the FTC or state consumer-protection offices. None of those are present on Oath. ## References [1] Oath Peptides / Oath Research COA archive (publicly searchable by peptide name, batch number, or CAS number; 199 batches visible as of May 2026; each certificate discloses purity %, endotoxin pass/fail, test date, and lab partner Freedom Diagnostics). [3] RealPeptidesScores.com — Oath Research vendor listing. Grade A — Recommended (audit dated 2026-05-09). Auditor's verbatim summary: 'Per-batch, portal-verifiable, and four times the cadence of the next-best vendor we audited.' Listing shows 142 of Oath's 199 batches (~29% incomplete) and still issues Grade A on the partial dataset. https://realpeptidescores.com/vendor/oath-research [4] amino.reviews / oath.reviews — independent verified-purchase review aggregator. 4.8/5 across 69 verified reviews; 180 verified lab tests on file. Rating distribution: 57 five-star, 11 four-star, 1 three-star, 0 two-star, 0 one-star. https://oath.reviews/ [9] Freedom Diagnostics — independent commercial laboratory in Franklin, Tennessee. CLIA registration 14D2263999, federally issued by the Centers for Medicare and Medicaid Services. Operating since 2023; serves multiple unrelated peptide vendors. https://freedomdiagnosticstesting.com/ [10] amino.reviews customer review — Nancy I., 2026-05-23: 'Sent my own sample of their tirzepatide for an independent test and it lined up with the posted COA.' Customer-funded independent retest of the same Tirzepatide product peptidescore.com alleged 'lead contamination' on, with the result matching Oath's posted COA. Featured in the dedicated nancy_retest_callout on /evidence. https://oath.reviews/reviews [13] CMS Clinical Laboratory Improvement Amendments (CLIA) public database — federally issued laboratory certifications, searchable by registration number. Freedom Diagnostics' CLIA 14D2263999 is verifiable through this database. https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments [16] Peptide Protocol Wiki — investigative piece, 'Finnrick Analytics: Transparency Concerns' (2026-02-24). Names Finnrick Analytics LLC as the operator of peptidescore.com; documents Finnrick's $279-per-month Premium program for the same peptide vendors it publicly rates; identifies investors as Kortschak Investments (pre-seed) and Naval Ravikant; CEO Raphaël Mazoyer. https://peptideprotocolwiki.com/blog/finnrick-analytics-transparency-concerns [17] Derek Pruski substack — 'The Truth About Finnrick and Independent' (2026-02-14). Independent commentary on Finnrick Analytics' pay-to-rate business model and the editorial concerns this raises for readers interpreting peptidescore.com ratings. https://derekpruski.substack.com/p/the-truth-about-finnrick-and-independent [18] Finnrick Analytics corporate identification — public records corroborating Finnrick Analytics LLC as the operating entity of peptidescore.com: Finnrick logo in peptidescore.com header; per-vendor disclosure 'tests conducted by or on behalf of Finnrick'; CEO Raphaël Mazoyer's LinkedIn profile listing 'Finnrick CEO'; corporate registration locating Finnrick Analytics LLC in Mountain View, California with Austin, Texas operations. https://www.linkedin.com/in/raphmaz [19] RealPeptidesScores.com — EQNO Scientific vendor listing. Grade D — 'Avoid — thin evidence.' Four COAs visible, most recent over 360 days old at audit. Used in this case file as the cross-reviewer-divergence anchor: the same vendor that Finnrick / peptidescore.com rates at Grade A with a perfect 10.0 is independently rated 'Avoid' by RealPeptidesScores, demonstrating Finnrick's calibration problem. https://realpeptidescores.com/vendor/eqno-scientific [20] peptidescore.com — vendor-scoring site operated by Finnrick Analytics LLC. Publishes the Grade E 'elevated lead contamination' claim against three Oath GLP-1 products (Retatrutide, Semaglutide, Tirzepatide) with test date Feb 6, 2026 that this case file dismantles in five layers. Referenced only for the purpose of identifying the source of the claim under critique. [21] ScamAdviser — automated young-domain trust scoring service. Trust Score 0 for oathresearch.com at scrape time. No user-submitted complaints reported behind the score; factors flagged are WHOIS privacy enabled, domain age under twelve months, DV-grade SSL certificate, and traffic-to-age ratio. [22] Scam-Detector — automated young-domain trust scoring service. Trust Score 38.6 for oathresearch.com at scrape time. Direct fetch returned 403; data captured via search-engine snippet aggregation. Same algorithmic methodology class as ScamAdviser. [23] gridinsoft — automated trust-scoring service. Score 78/100 ('Safe to use') for oathpeptides.com. Cited in this case file to establish algorithmic inconsistency: three algorithms (ScamAdviser 0, Scam-Detector 38.4, gridinsoft 78/100) score the same domain class with wildly divergent verdicts. Not hyperlinked per the no-link rule applied to algorithmic scanners. --- A skeptical investigator's case file on one research-peptide vendor's scam allegations — ticketed, dispositioned, and signed off from this side of the masthead, with no commercial relationship to the company under investigation.